Zydus Cadila gets tentative nod from USFDA to market cancer drug, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Ibrutinib tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg, Zydus Cadila said in a statement., The company has received tentative approval from the United States Food and Drug Administration (USFDA) to market Ibrutinib tablets, in the strengths of 140 mg, 280 mg, 420 mg and 560 mg, Zydus Cadila said in a statement., , Read More

Leave a Reply

Your email address will not be published.